The LRG is here to help, join our community of patients, caregivers and specialists!
We have the latest in GIST news and research to help manage your treatment!
We are accepting applications to be listed among our GIST Specialists.
The Latest News from the Life Raft Group
Clinical trials have given us a lot of information about dosing Gleevec. Unfortunately, however, doctors and researchers do not always reach the same conclusions about what the data is telling them. Measuring Gleevec drug levels in patients may provide a measure of reassurance to patients and doctors that they are on the right course with regards to dosing.
March, 2005 – Novartis drug can inhibit secondary KIT mutations By Jerry Call Life Raft Group science coordinator Recently reported research further defines the mechanisms of resistance that GIST tumors use to thwart Gleevec. The researchers also report that the Novartis drug, PKC412, may be able to overcome this resistance in some cases. Maria […]
Data raises concerns over long-term viability of lower Gleevec doses By Jerry Call with Norman Scherzer January, 2005 – One reason that side effects from Gleevec often get better over time is that levels of Gleevec tend to decrease over time in many patients, according to a new report. This may also explain why — […]